News

Genzyme Phase 3 Study of Eliglustat Meets Primary Endpoint

18 October 2012

Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for GD Meets Primary Endpoint

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that ENGAGE, the first Phase 3 trial of its …

read more »

Market approval of Elelyso by the Israeli Ministry of Health

3 October 2012

Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli Ministry of Health

CARMIEL, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) …

read more »

India to join the EGA

27 September 2012

We are pleased to announce that the LSD Support Society of India has joined the EGA as an associate member.

Mexico to join the EGA

24 May 2012

We are pleased to announce that Mexico has joined the EGA as an associate member.

Bosnia & Herzegovina to join EGA

3 May 2012

We are pleased to announce that Bosnia & Herzegovina joined the EGA as full member.

FDA approved Elelyso (taliglucerase alfa)

1 May 2012

FDA approves new orphan drug to treat a form of Gaucher disease (01.05.2012)

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare …

read more »

Macedonia and Switzerland to join EGA

19 April 2012

We are pleased to announce that Macedonia and Switzerland joined the EGA as full members.

Humanitarian Aid (March 2012)

26 March 2012

Humanitarian Aid has always been a priority for the EGA...

...and will continue to be a priority in the future, we have pledged to help any Gaucher patient who ask us for help where ever they live. However the “Gaucher-world” has …

read more »

Shire Announces European Approval of Manufacturing Facility for VPRIV

22 February 2012

Shire Announces European Approval of Manufacturing Facility for VPRIV® (velaglucerase alfa)

European Medicines Agency Approval Adds Significant Capacity for the Manufacture of Shire’s Enzyme Replacement Therapies

Lexington, MA, US …

read more »

Press release - Genzyme: Four-Year Data from Phase 2 Trial ...

9 February 2012

Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints

09/02/2012

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the …

read more »